Skip to main content

Investigating the physical stability of repackaged medicines stored into commercially available multicompartment compliance aids (MCAs)

Raimi-Abraham, B.T., Garcia del Valle, A., Varon Galcera, C., Barker, S.A., Orlu, M. (2017) Investigating the physical stability of repackaged medicines stored into commercially available multicompartment compliance aids (MCAs). Journal of Pharmaceutical Health Services Research, 8 (2). pp. 81-89. ISSN 1759-8885. (doi:10.1111/jphs.12176) (KAR id:78840)

PDF Publisher pdf
Language: English

Download (508kB) Preview
[thumbnail of Raimi-Abraham_et_al-2017-Journal_of_Pharmaceutical_Health_Services_Research.pdf]
This file may not be suitable for users of assistive technology.
Request an accessible format
Official URL


Background: Compliance aids are devices which have been developed and are currently used to assist individuals in their medicines management. The use of compliance aids involves the transfer of medicines from the manufacturers' original packaging and repackaged into an multicompartment compliance aid (MCA). MCAs do not guarantee the same level of protection compared to manufacturer's original packaging. Objective: The aim of this study was to investigate the stability profile of atenolol, aspirin and lansoprazole dosage forms repackaged together in two different commercially available MCAs. Methods: In a laboratory in the United Kingdom, the physical stability of the formulations repackaged into two commercially available brands of MCAs was evaluated. After 8 weeks of storage (under controlled ambient conditions), changes in the disintegration (tablets only) and dissolution properties (all formulations) were examined in accordance with British Pharmacopoeia (BP) specifications. Key findings: Findings from this study confirm that changes in solid-dosage form quality are observed when repackaged into MCAs compared to manufacturers packaging resulting in differences in in-vitro dissolution performance. However, even with these changes, overall product performance was acceptable and within BP specifications. Conclusion: There is a need for greater collaboration in this area between manufacturers, hospital and community pharmacists, academics and policymakers to increase the data available on the physical stability and in turn performance of medicines repackaged into MCAs.

Item Type: Article
DOI/Identification number: 10.1111/jphs.12176
Uncontrolled keywords: compliance, multicompartment compliance aid, older patient, repackaging, stability, acetylsalicylic acid, atenolol, lansoprazole, Article, controlled study, drug formulation, drug manufacture, drug packaging, drug solubility, drug stability, drug storage, health care policy, in vitro study, multicompartment compliance aid, pharmacist, priority journal, tablet disintegration, United Kingdom
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Susan Barker
Date Deposited: 26 Nov 2019 16:40 UTC
Last Modified: 16 Feb 2021 14:09 UTC
Resource URI: (The current URI for this page, for reference purposes)
Barker, S.A.:
  • Depositors only (login required):


Downloads per month over past year